Thus, therapeutic strategies aiming to regulate adiponectin concentrations and AdipoR1/2 activation are considered an encouraging tool in the management of obesity-related cancer, such as cervical, ovarian, endometrial, while a lot of controversial issues still remain in adiponectin treatment of breast cancer. Here, ADIPOR1 is linked to breast cancer.